[go: up one dir, main page]

MX2018015797A - Tratamiento guiado por exosoma de cáncer. - Google Patents

Tratamiento guiado por exosoma de cáncer.

Info

Publication number
MX2018015797A
MX2018015797A MX2018015797A MX2018015797A MX2018015797A MX 2018015797 A MX2018015797 A MX 2018015797A MX 2018015797 A MX2018015797 A MX 2018015797A MX 2018015797 A MX2018015797 A MX 2018015797A MX 2018015797 A MX2018015797 A MX 2018015797A
Authority
MX
Mexico
Prior art keywords
exosome
cancer
guided treatment
treatment
exosomes
Prior art date
Application number
MX2018015797A
Other languages
English (en)
Inventor
Soon-Shiong Patrick
Original Assignee
Nant Holdings Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nant Holdings Ip Llc filed Critical Nant Holdings Ip Llc
Publication of MX2018015797A publication Critical patent/MX2018015797A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

Sistemas y metodos de monitoreo de tratamiento de una informacion de uso de paciente obtenida de los exosomas, en el donde el objetivo de tratamiento que fue identificado a partir de un tumor se sigue en los exosomas en un fluido biologico fuera del tumor.
MX2018015797A 2016-06-21 2017-06-21 Tratamiento guiado por exosoma de cáncer. MX2018015797A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352753P 2016-06-21 2016-06-21
PCT/US2017/038515 WO2017223186A1 (en) 2016-06-21 2017-06-21 Exosome-guided treatment of cancer

Publications (1)

Publication Number Publication Date
MX2018015797A true MX2018015797A (es) 2019-05-16

Family

ID=60784697

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015797A MX2018015797A (es) 2016-06-21 2017-06-21 Tratamiento guiado por exosoma de cáncer.

Country Status (11)

Country Link
US (1) US20190234955A1 (es)
EP (1) EP3472623A4 (es)
JP (1) JP2019527343A (es)
KR (1) KR20190032374A (es)
CN (1) CN109716135A (es)
AU (1) AU2017280204A1 (es)
CA (1) CA3027478A1 (es)
IL (1) IL263835A (es)
MX (1) MX2018015797A (es)
SG (1) SG11201811070SA (es)
WO (1) WO2017223186A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017008422A (es) 2014-12-30 2017-10-02 Dow Agrosciences Llc Compuestos de picolinamida con actividad fungicida.
TW201902357A (zh) * 2017-05-02 2019-01-16 美商陶氏農業科學公司 用作種子處理之無環吡啶醯胺
TWI724521B (zh) * 2018-08-30 2021-04-11 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 利用胞外囊泡診斷疾病的方法
WO2021142088A1 (en) * 2020-01-07 2021-07-15 The Trustees Of The University Of Pennsylvania Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies
CA3169677A1 (en) * 2020-02-27 2021-09-02 The Trustees Of The University Of Pennsylvania Methods of using a multi-analyte approach for diagnosis and staging a disease
CN115449555B (zh) * 2022-10-26 2023-10-13 山东大学 Adgra2作为乳腺癌化疗疗效和预后评价生物标志物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108294735B (zh) * 2012-03-13 2021-09-07 西门子公司 用于冠状动脉狭窄的非侵入性功能评估的方法和系统
US11180812B2 (en) * 2012-08-17 2021-11-23 Cornell University Use of DNA in circulating exosomes as a diagnostic marker for metastatic disease
EP2985605A4 (en) * 2013-04-08 2017-02-15 Theoria Science Inc. Method for detecting colon cancer
CN105431552B (zh) * 2013-04-12 2020-03-03 香港中文大学 多组学标记在预测糖尿病中的用途
DK3076949T3 (da) * 2013-12-04 2019-11-25 Univ Texas Fremgangsmåde til isolering af kræftcelle-afledte eksosomer
US20170102397A1 (en) * 2014-06-27 2017-04-13 Xy Evergreen Technology Company Method for enriching cns-derived exosomes
CN104450901B (zh) * 2014-11-27 2016-09-21 广州赛哲生物科技股份有限公司 快速诊断川崎病的核酸标记物及其试剂盒

Also Published As

Publication number Publication date
CN109716135A (zh) 2019-05-03
WO2017223186A1 (en) 2017-12-28
AU2017280204A1 (en) 2019-01-24
EP3472623A4 (en) 2020-01-15
CA3027478A1 (en) 2017-12-28
US20190234955A1 (en) 2019-08-01
IL263835A (en) 2019-02-03
KR20190032374A (ko) 2019-03-27
JP2019527343A (ja) 2019-09-26
EP3472623A1 (en) 2019-04-24
SG11201811070SA (en) 2019-01-30

Similar Documents

Publication Publication Date Title
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2018015797A (es) Tratamiento guiado por exosoma de cáncer.
MX2016004489A (es) Sistemas y metodos para tratar el cancer y/o aumentar la funcion de organos.
EA202091602A1 (ru) Системы и способы для обработки биологических жидкостей
IL252796A0 (en) Therapeutic, diagnostic and prognostic methods for bladder cancer
MX379621B (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer
EP3383303C0 (en) SYSTEM FOR MAPPING THE FUNCTIONAL NERVES INNERVING THE ARTERY WALL, 3D MAPPING AND CORRESPONDING CATHETERS
WO2016070051A3 (en) Combination therapy for treatment of disease
EA201792642A1 (ru) Способы диагностики для т-клеточной терапии
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
EA201791736A1 (ru) Комбинированная терапия для лечения рака
PH12016501978A1 (en) Treatment of nafld and nash
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
SMT202200199T1 (it) Metodi di trattamento del cancro del seno ar+.
BR112017014481A2 (pt) máquinas de tratamento com fluido médico e sistemas e métodos relacionados.
LT3458610T (lt) Krūties vėžio terapinis gydymas, remiantis c-maf būkle
WO2016191675A3 (en) Antibodies against glypican-3 and their uses in cancer diagnosis and treatment
TW201613587A (en) Medical treatments based on anamorelin
WO2017192662A3 (en) Methods for identifying treatment targets based on multiomics data
PH12019500725A1 (en) Methods of treating acute kidney injury
MX389899B (es) Compuesto macrocíclico y sus usos.
TW201614237A (en) Markers for identifying patients responsive to anti-PD-L1 antibody therapy
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
ZA201708686B (en) Nanoparticles for use as a therapeutic vaccine
MX2019001635A (es) Terapia de combinacion con un inhibidor de mek, un inhibidor del eje de pd-1, y un inhibidor de vegf.